Navigation Links
Peregrine in Medical Technology

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner Peregrine Pharmaceuticals at the 100th Annual Meeting of the...

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established Tumors in a Preclinical Breast Cancer Model -- -- R84 Is Being ...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, the human antibody therapeutics company announced today that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

... TUSTIN, Calif., June 3 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today high... posted at www.peregrineinc.com . About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

... TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today annou...nced solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

...TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical...hia (PA): AACR; 2009. Abstract nr 5463 About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

...TUSTIN, Calif., April 21 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinica... Medical Center in Dallas, a scientific advisor to peregrine and co-author of one of the AACR presentations. "...f preclinical studies by a team of scientists from peregrine Pharmaceuticals and Affitech A/S used a fully huma...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

...TUSTIN, Calif., April 20 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), today ann...d solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

...tion Criteria in Solid Tumors (RECIST) criteria. peregrine president and CEO, Steven W. King noted, "We are v...advanced solid cancers is also continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... - peregrine Achieves Milestone as Third Phase II Trial in Its ...CH) and Good Clinical Practices (GCP) standards. peregrine recently reported that a Phase II trial assessing ...advanced solid cancers is also continuing. About peregrine Pharmaceuticals ...

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer

...l in advanced solid cancers is continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in- house manufacturing capabilities thro...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

...l in advanced solid cancers is continuing. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in-house manufacturing capabilities throu...

Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio

...ti-aminophospholipid agents. The new patents grant peregrine broad anti-viral method claims using a range of ph...r substances. "These are significant patents for peregrine that substantially expand our intellectual propert...at the breadth of the issued claims, which provide peregrine with U.S. patent coverage for methods of combating...

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...unday, June 1, 2008 2:00 PM - 6:00 PM CDT. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...lead product candidates bavituximab and Cotara(R). peregrine also has in-house manufacturing capabilities throu...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab

...lead author Dr. Monica Friedrich and colleagues at peregrine show that both bavituximab and PGN635 cause the de...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... that enhances innate anti-tumor immune responses, peregrine Pharmaceuticals, Inc., April 15, 2008, 8:00 AM - 1...

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... TX, April 14, 2008, 1:00 PM - 4:00 PM PDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ...ted in part by a sponsored research agreement with peregrine Pharmaceuticals and by a grant from the U.S. Depar...las, TX, April 14, 2008, 2:10 PM - 2:25 PM About peregrine Pharmaceuticals ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct three ... TX, April 14, 2008, 8:00 AM -12:00 PM PDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents

...se stabilization in 50% of the evaluable patients. peregrine recently received regulatory approval to conduct t...t the Hyatt Regency Hotel in La Jolla, CA. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer

...se stabilization in 50% of the evaluable patients. peregrine has received regulatory approval to conduct two ad...in patients co- infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

... -- peregrine Has Now Received Regulatory Approval for Three Pha...se stabilization in 50% of the evaluable patients. peregrine has now received regulatory approval for three Pha... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals ...

Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

...se stabilization in 50% of the evaluable patients. peregrine has filed three Phase II cancer protocols to study... in patients co-infected with HCV and HIV. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV

...tible to the development of anti-viral resistance. peregrine has completed two bavituximab Phase I monotherapy ...trials for the treatment of solid cancers. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer

...ter ended July 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Cont...

Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV

...tible to the development of anti-viral resistance. peregrine has completed two bavituximab Phase l monotherapy ...h encouraging signs of anti-viral activity. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer

...ar ended April 30, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release. Cont...

Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

...as supported by the U.S. Army Medical Research and Materiel Command under W81XWH-06-1-0050 (DOD PC05031 grant) and a sponsored research agreement with peregrine Pharmaceuticals, Inc. Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregri...

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

...as supported by the U.S. Army Medical Research and Materiel Command under W81XWH-06-1-0050 (DOD PC05031 grant) and a sponsored research agreement with peregrine Pharmaceuticals, Inc. Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregri...

Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

...half of its victims within 14 months of diagnosis. peregrine believes that combined positive data from this new...a by the U.S. Food and Drug Administration. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

..., Calif., April 16, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. a clinical stage biopharmace...ted in part by a sponsored research agreement with peregrine Pharmaceuticals. The fully human antibody R3 used ...dical Ctr., Dallas, TX, Affitech AS, Oslo, Norway, peregrine Pharmaceuticals Inc., Tustin, CA, UT-MD Anderson, ...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

..., Calif., April 17, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma...ted in part by a sponsored research agreement with peregrine Pharmaceuticals and by a grant from the U.S. Depar...allas, TX, Apr 16, 2007, 1:00 PM - 5:00 PM About peregrine Pharmaceuticals ...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

..., Calif., April 18, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma..., TX, Apr 17, 2007, 8:00 AM - 12:00 PM EDT About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

..., Calif., April 18, 2007 /PRNewswire-FirstCall/ -- peregrine Pharmaceuticals, Inc. , a clinical stage biopharma...or virus infections including chronic hepatitis C, peregrine also intends to assess the utility of the new clas...r the Cure and a sponsored research agreement with peregrine Pharmaceuticals Inc. Number 3539: Inhibition of ...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

... programs reinforce our belief that the future for peregrine has never been brighter, and we look forward to pr...ted Anti-PS Antibody Researchers affiliated with peregrine presented a number of preclinical studies demonstr...r development programs. Researchers working with peregrine presented data on progress in the company's VTA co...

Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients

...d in combination with chemotherapy or radiation. peregrine intends to present more complete data from this tr...priate scientific meeting later this year. About peregrine Pharmaceuticals peregrine Pharmaceuticals, Inc. is a biopharmaceutical compa...
Other Tags
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
(Date:8/28/2015)... Abilene, Texas (PRWEB) , ... August 28, 2015 , ... ... penned a new publication and pleads for swift actions to be taken in ... of unnatural disasters. , Yisrayl says scientists have yet to understand fully the ...
(Date:8/28/2015)... ... 2015 , ... Where can successful, well educated, or attractive ... up to help quality singles find dating partners or ideal matches. , ... well educated, or attractive. , It updates profiles under the category of " ...
(Date:8/27/2015)... ... August 28, 2015 , ... Best-selling Author Vanessa ... care through “The Language of Flowers,” has joined the Youth Villages national board ... organization’s YVLifeSet program, was piqued by her passion for helping foster youth. Her ...
(Date:8/27/2015)... ... , ... Mesa Community College graduate, Andrew Sypher (Mesa), is one ... rigor, leadership and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, ... medallion and a $7,500 scholarship to assist in his goal of becoming a foreign ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
Breaking Medicine News(10 mins):Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 2Health News:MillionaireMatchmakerOnline.net Collects and Updates Newest Millionaire and Quality Single Profiles on the Page of Millionaire Matchmaker Online Canada. 3Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 2Health News:Best-selling Author Vanessa Diffenbaugh Joins Youth Villages National Board of Directors 3Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3
Other Contents